A tax on luxury: HTLV-I infection of CD4+CD25+ Tregs
- PMID: 15864345
- PMCID: PMC1087186
- DOI: 10.1172/JCI25130
A tax on luxury: HTLV-I infection of CD4+CD25+ Tregs
Abstract
Almost a quarter of a century ago, Oldstone and colleagues proposed that infection of cells by noncytopathic viruses may lead to an alteration of the cells' ability to produce certain products or perform certain tasks, i.e., inhibition of "luxury function." In this issue of the JCI, this topic has been revisited by Yamano et al., who demonstrate that human T cell lymphotropic virus type I (HTLV-I) infection of CD4(+)CD25(+) Tregs in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) results in a decrease in FOXP3 mRNA and protein expression. This leads to the inability of HTLV-I-infected CD4(+)CD25(+) Tregs to inhibit the proliferation of CD4(+)CD25(-) Tregs, due to the effect of the HTLV-I tax gene. Defects in the Treg population could be responsible for the large numbers of virus-specific T cells and occurrence of lymphoproliferation and inflammatory autoimmune disease in HAM/TSP patients.
Figures

Comment on
-
Virus-induced dysfunction of CD4+CD25+ T cells in patients with HTLV-I-associated neuroimmunological disease.J Clin Invest. 2005 May;115(5):1361-8. doi: 10.1172/JCI23913. J Clin Invest. 2005. PMID: 15864353 Free PMC article.
Similar articles
-
Virus-induced dysfunction of CD4+CD25+ T cells in patients with HTLV-I-associated neuroimmunological disease.J Clin Invest. 2005 May;115(5):1361-8. doi: 10.1172/JCI23913. J Clin Invest. 2005. PMID: 15864353 Free PMC article.
-
Molecular and clinical effects of betamethasone in human T-cell lymphotropic virus type-I-associated myelopathy/tropical spastic paraparesis patients.J Med Virol. 2011 Sep;83(9):1641-9. doi: 10.1002/jmv.22131. J Med Virol. 2011. PMID: 21739457
-
Different cytokine production in tax-expressing cells between patients with human T cell lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis and asymptomatic HTLV-I carriers.J Infect Dis. 2003 Apr 1;187(7):1116-25. doi: 10.1086/368379. Epub 2003 Mar 13. J Infect Dis. 2003. PMID: 12660926
-
[Immunopathogenesis and treatment of the myelopathy associated to the HTLV-I virus].Rev Neurol. 2009 Feb 1-15;48(3):147-55. Rev Neurol. 2009. PMID: 19206063 Review. Spanish.
-
Adult T cell leukemia/lymphoma: FoxP3(+) cells and the cell-mediated immune response to HTLV-1.Adv Cancer Res. 2011;111:163-82. doi: 10.1016/B978-0-12-385524-4.00004-0. Adv Cancer Res. 2011. PMID: 21704832 Review.
Cited by
-
CD4+ T cell subsets and Tax expression in HTLV-1 associated diseases.Pathog Glob Health. 2013 Jun;107(4):202-6. doi: 10.1179/2047773213Y.0000000091. Pathog Glob Health. 2013. PMID: 23816512 Free PMC article.
References
-
- Uchiyama T. Human T cell leukemia virus type I (HTLV-I) and human diseases. Annu. Rev. Immunol. 1997;15:15–37. - PubMed
-
- Oldstone MBA, et al. Virus-induced alterations in homeostasis: alteration in differentiated functions of infected cells in vivo. Science. 1982;218:1125–1127. - PubMed
-
- Orland JR, et al. Prevalence and clinical features of HTLV neurologic disease in the HTLV Outcomes Study. Neurology. 2003;61:1588–1594. - PubMed
-
- Murphy EL, et al. Increased prevalence of infectious diseases and other adverse outcomes in human T lymphotropic virus types I- and II-infected blood donors. Retrovirus Epidemiology Donor Study (REDS) Study Group. J. Infect. Dis. 1997;176:1468–1475. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous